ACase-Based Introduction to TEVIMBRA for the 1L Treatment of Adult Patients with ESCC and GC/GEJC – Nov 18
ABOUT
Join us for a 60-minute discussion on the role of TEVIMBRA (tislelizumab-jsgr), a newly approved immunotherapy specifically designed to optimize PD-1 binding and deliver more robust T-cell activation. Using a case-based approach, we will explore key clinical data and discuss treatment decision-making as well as key considerations for optimizing patient care. This session is designed for medical oncologists and other healthcare professionals to deepen their understanding of TEVIMBRA and its use in the management of ESCC and GC/GEJC.
DATE & TIME
Tuesday, November 18, 2025
6:30 PM
SPEAKER
Kirollos S. Hanna, PharmD, BCPS, BCOP, Director of Pharmacy, Minnesota Oncology – St. Paul
TO RSVP: Please register by visiting https://beigene-portal.myeventview.net/Register/04E_QQliePPK61nedfMkww
Or by contacting: Lisa Schmidt, call 408-202-6262, or email lisa.schmidt@beonemed.com
LOCATION
LB Steak Santana Row, 334 Santa Row Ste. 1000, San Jose, CA 95128, (408) 413-3939